Associated Genetic Biomarkers
SPRY2 is altered in 0.42% of all cancers with conventional glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, diffuse astrocytoma, and encapsulated glioma having the greatest prevalence of alterations .
The most common alterations in SPRY2 are SPRY2 G8D (0.13%), SPRY2 A175V (0.09%), SPRY2 D235G (0.09%), SPRY2 E169D (0.07%), and SPRY2 E87K (0.07%) .
SPRY2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial that contains SPRY2 status as an inclusion criterion, 1 is phase 2 (0 open).
Trials with SPRY2 status in the inclusion eligibility criteria most commonly target adenocarcinoma of the gastroesophageal junction and gastric adenocarcinoma .
The most frequent alteration to serve as an inclusion eligibility criterion is SPRY2 Expression .
Docetaxel and selumetinib are the most frequent therapies in trials with SPRY2 as an inclusion criteria .
Significance of SPRY2 in Diseases
Adenocarcinoma Of The Gastroesophageal Junction +
SPRY2 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 0 are open and 1 is closed. Of the trial that contains SPRY2 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (0 open) .
Gastric Adenocarcinoma +
SPRY2 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains SPRY2 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.